ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 51 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $232,383 | -32.6% | 43,763 | +20.9% | 0.00% | – |
| Q2 2023 | $344,964 | +84.1% | 36,184 | +112.4% | 0.00% | – |
| Q1 2023 | $187,396 | -20.5% | 17,036 | +6.9% | 0.00% | – |
| Q4 2022 | $235,852 | -19.0% | 15,936 | +4.8% | 0.00% | – |
| Q3 2022 | $291,000 | +15.5% | 15,213 | +28.9% | 0.00% | – |
| Q2 2022 | $252,000 | +50.0% | 11,804 | +35.2% | 0.00% | – |
| Q1 2022 | $168,000 | -7.2% | 8,732 | 0.0% | 0.00% | – |
| Q4 2021 | $181,000 | -13.4% | 8,732 | 0.0% | 0.00% | – |
| Q3 2021 | $209,000 | +102.9% | 8,732 | +130.8% | 0.00% | – |
| Q2 2021 | $103,000 | -17.6% | 3,783 | -12.7% | 0.00% | – |
| Q1 2021 | $125,000 | +83.8% | 4,333 | +79.5% | 0.00% | – |
| Q4 2020 | $68,000 | +7.9% | 2,414 | +11.9% | 0.00% | – |
| Q3 2020 | $63,000 | +31.2% | 2,157 | +37.3% | 0.00% | – |
| Q2 2020 | $48,000 | 0.0% | 1,571 | -2.8% | 0.00% | – |
| Q1 2020 | $48,000 | – | 1,617 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $296,569,000 | 22.84% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $111,937,000 | 7.03% |
| Pivotal bioVenture Partners Investment Advisor LLC | 671,716 | $18,895,000 | 6.23% |
| Omega Fund Management, LLC | 640,199 | $18,009,000 | 2.70% |
| Orbimed Advisors | 6,073,850 | $170,857,000 | 1.50% |
| Vivo Capital, LLC | 867,170 | $24,393,000 | 1.09% |
| Octagon Capital Advisors LP | 100,000 | $2,813,000 | 0.98% |
| Altium Capital Management LP | 62,962 | $1,771,000 | 0.66% |
| RA Capital Management | 1,165,184 | $32,777,000 | 0.46% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 8,505 | $239,000 | 0.14% |